Aevit (Capsules) Instructions for Use
ATC Code
A11JA (Vitamins in combination)
Active Substances
Retinol (Rec.INN registered by WHO)
Tocopherol (Ph.Eur. European Pharmacopoeia)
Clinical-Pharmacological Group
Vitamin complex
Pharmacotherapeutic Group
Vitamins; other combined vitamin preparations; combinations of vitamins
Pharmacological Action
A combined medicinal product, the action of which is determined by the properties of the fat-soluble vitamins A and E that are part of it.
Retinol (vitamin A) is a necessary component for the normal function of the retina of the eye: binding with opsin (the red pigment of the retina), it forms the visual purple rhodopsin, which is necessary for visual adaptation in the dark. Vitamin A is necessary for bone growth, normal reproductive function, embryonic development, and for the regulation of division and differentiation of the epithelium (enhances the reproduction of skin epithelial cells, rejuvenates the cell population, and inhibits keratinization processes). Vitamin A participates as a co-factor in various biochemical processes.
The function of α-tocopherol (vitamin E): as an antioxidant, it inhibits the development of free radical reactions, prevents the formation of peroxides that damage cellular and subcellular membranes, which is important for the development of the body, the normal function of the nervous and muscular systems. Together with selenium, it inhibits the oxidation of unsaturated fatty acids (a component of the microsomal electron transfer system), and prevents hemolysis of erythrocytes. It is a co-factor of some enzyme systems. It restores capillary circulation, normalizes capillary and tissue permeability, and increases tissue resistance to hypoxia.
Pharmacokinetics
Tocopherol when taken orally is slowly absorbed, approximately 50% of the taken dose of the drug, Cmax after 4 hours. The presence of bile acids is necessary for absorption. It is deposited in the adrenal glands, pituitary gland, testes, adipose and muscle tissue, erythrocytes, and liver. It is metabolized and excreted from the body (unchanged and in the form of metabolites) with bile (over 90%) and urine (about 6%).
Retinol when taken orally, retinol is absorbed almost completely, even with excessive administration, no more than 10% of the administered amount is excreted with feces. In the process of metabolism, retinyl palmitate, retinol, retinal, and retinoic acid are formed. It is distributed unevenly in the body: the largest amount is in the liver and retina, less is in the kidneys, heart, fat depots, lungs, lactating mammary gland, in the adrenal glands and other endocrine glands. Retinol, retinal, retinoic acid are excreted by hepatocytes as part of bile, retinoylglucuronide is excreted in the urine.
The elimination of fat-soluble vitamins (tocopherol and retinol) is slow, so repeated doses lead to accumulation.
Indications
Hypo- and avitaminosis A and E, as well as conditions of increased body demand for vitamins A and E and/or reduced intake into the body: gastrectomy, diarrhea, steatorrhea, celiac disease, Crohn’s disease, malabsorption syndrome, chronic cholestasis, liver cirrhosis, biliary atresia, obstructive jaundice, cystic fibrosis of the pancreas, tropical sprue, infectious diseases (including chronic and “cold” ones), hemeralopia, xerophthalmia, keratomalacia, inadequate and unbalanced nutrition (including parenteral nutrition), rapid weight loss, nicotine dependence, drug addiction, state of prolonged stress, taking cholestyramine, colestipol, mineral oils, neomycin, iron-containing products, when prescribing a diet with an increased content of polyunsaturated fatty acids, hyperthyroidism.
Peripheral neuropathy, necrotizing myopathy, abetalipoproteinemia.
ICD codes
| ICD-10 code | Indication |
| A09 | Other and unspecified gastroenteritis and colitis of infectious origin |
| E05 | Thyrotoxicosis [hyperthyroidism] |
| E50 | Vitamin A deficiency |
| E56.0 | Vitamin E deficiency |
| E63.1 | Disparate intake of food elements |
| E78.6 | Lipoprotein deficiency |
| E84.1 | Cystic fibrosis with intestinal manifestations |
| F11 | Mental and behavioral disorders due to opioid use |
| F17 | Mental and behavioural disorders due to use of tobacco |
| G62.9 | Polyneuropathy, unspecified |
| G72 | Other myopathies |
| H04.1 | Other disorders of lacrimal gland (dry eye syndrome) |
| H18.4 | Corneal degeneration |
| H53.1 | Subjective visual disturbances |
| J06.9 | Acute upper respiratory infection, unspecified |
| K50 | Crohn's disease [regional enteritis] |
| K59.1 | Functional diarrhea |
| K74 | Fibrosis and cirrhosis of liver |
| K83.9 | Disease of biliary tract, unspecified |
| K90.0 | Coeliac disease |
| K90.1 | Tropical sprue |
| K90.3 | Pancreatic steatorrhea |
| K90.4 | Malabsorption due to intolerance, not elsewhere classified |
| K91.1 | Postgastric surgery syndromes |
| R17 | Hyperbilirubinemia, with or without jaundice, not elsewhere classified |
| Y57.8 | Other drugs and medicaments |
| Z73.3 | Stress, not elsewhere classified (physical and mental strain) |
| ICD-11 code | Indication |
| 1A40.Z | Infectious gastroenteritis or colitis, unspecified |
| 5A02.Z | Thyrotoxicosis, unspecified |
| 5B55.Z | Vitamin A deficiency, unspecified |
| 5B58 | Vitamin E deficiency |
| 5B7Z | Malnutrition, unspecified |
| 5C81.Z | Hypolipoproteinemia, unspecified |
| 6C43.Z | Disorders due to opioid use, unspecified |
| 6C4A.Z | Disorders due to nicotine use, unspecified |
| 8C4Z | Disorders of nerve roots, plexuses or peripheral nerves, unspecified |
| 8C8Z | Secondary myopathies, unspecified |
| 8D40.1 | Neuropathy due to nutritional deficiency |
| 9A1Z | Diseases of the lacrimal system, unspecified |
| 9A78.4 | Corneal degeneration |
| 9D51 | Transient vision loss |
| 9D5Z | Subjective visual disturbances, unspecified |
| CA07.0 | Acute upper respiratory tract infection of unspecified site |
| CA25.1 | Atypical cystic fibrosis |
| CA25.Z | Cystic fibrosis, unspecified |
| DA95 | Coeliac disease |
| DA96.01 | Tropical sprue |
| DA96.02 | Malabsorption or intolerance of specific nutrients |
| DA96.1 | Protein-losing enteropathy |
| DA96.Z | Malabsorption syndrome or protein-losing enteropathy, unspecified |
| DB93 | Fibrosis or cirrhosis of liver |
| DC10.Z | Acquired structural (organic) changes of gallbladder or bile ducts, unspecified |
| DC14.Z | Diseases of the biliary tract, unspecified |
| DC1Z | Diseases of gallbladder and biliary tract, unspecified |
| DC35.2 | Pancreatic steatorrhea |
| DD70.Z | Crohn's disease, unspecified location |
| DD91.2 | Functional diarrhea |
| DD93.Y | Other specified functional gastrointestinal disorders in infants, toddlers and school-age children |
| DD9Z | Functional gastrointestinal disorders, unspecified |
| DE11 | Dumping syndrome |
| ME10.1 | Unspecified jaundice |
| PL00 | Drugs, medicaments or biological substances causing injury or harm in therapeutic use |
| QE01 | Stress, not elsewhere classified |
| CA25.0 | Classic cystic fibrosis |
| DB98.74 | Secondary portal hypertension |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Take orally. Swallow the capsule whole with a sufficient amount of water.
Adhere strictly to the individual dosing regimen established by a physician. The regimen is determined by the specific indication, severity of the condition, and patient factors.
For the treatment of avitaminosis A and E, the typical adult dose is one capsule (100,000 IU vitamin A, 100 mg vitamin E) per day.
The duration of therapy is determined by the physician. Do not exceed the prescribed daily dose or treatment duration to avoid the risk of hypervitaminosis.
For conditions of increased demand or malabsorption (e.g., post-gastrectomy, chronic cholestasis, cystic fibrosis, Crohn’s disease), the dosage and duration are set individually based on clinical need.
In cases of peripheral neuropathy or necrotizing myopathy, the therapeutic course may be prolonged; follow medical supervision.
This product contains high, therapeutic doses of vitamins and is not intended for prophylactic use or for self-medication without a diagnosis.
Contraindicated in children and adolescents under 18 years of age, during pregnancy, and breastfeeding.
Use with caution in elderly patients and in those with severe liver or renal impairment, thyrotoxicosis, or a history of cholelithiasis.
Adverse Reactions
Systemic reactions allergic reactions.
From the digestive system pain in the epigastric region, dyspeptic disorders (nausea, vomiting, diarrhea); with long-term use in large doses, exacerbation of cholelithiasis and chronic pancreatitis is possible.
Local reactions (with intramuscular injection) – pain, infiltrate, calcification of soft tissues.
Contraindications
Hypersensitivity, hypervitaminosis A and E, childhood (under 18 years), pregnancy, lactation period.
With caution
Thyrotoxicosis, cholecystitis, conditions accompanied by increased vascular permeability (CHF, chronic glomerulonephritis, etc.), liver cirrhosis, viral hepatitis, renal failure, alcoholism, old age, hypoprothrombinemia (against the background of vitamin K deficiency – may be enhanced at a vitamin E dose of more than 400 IU).
Use in Pregnancy and Lactation
Contraindicated during pregnancy and during lactation (breastfeeding).
Use in Hepatic Impairment
With caution liver cirrhosis, viral hepatitis, renal failure.
Use in Renal Impairment
With caution renal failure, conditions accompanied by increased vascular permeability (CHF, chronic glomerulonephritis, etc.).
Pediatric Use
Contraindicated under the age of 18 years.
Geriatric Use
With caution old age.
Special Precautions
To avoid the development of hypervitaminosis A and E, the recommended doses should not be exceeded.
When using the drug, one should take into account the high content of vitamin A (100 thousand IU) in it, as well as the fact that it is a therapeutic, not a prophylactic drug.
A diet with an increased content of Se and sulfur-containing amino acids reduces the need for vitamin E.
Drug Interactions
Retinol weakens the effect of calcium preparations, increases the risk of hypercalcemia.
Cholestyramine, colestipol, mineral oils, neomycin reduce the absorption of vitamins A and E (an increase in their dose may be required).
Oral contraceptives increase the concentration of retinol in plasma.
Isotretinoin increases the risk of retinol intoxication.
Simultaneous use of tetracycline and retinol in high doses (50 thousand IU and above) increases the risk of intracranial hypertension.
Tocopherol (vitamin E) enhances the effect of corticosteroids, NSAIDs, antioxidants, increases the effectiveness and reduces the toxicity of vitamins A, D, cardiac glycosides. Prescription of vitamin E in high doses can cause deficiency of vitamin A in the body.
Tocopherol (vitamin E) increases the effectiveness of antiepileptic drugs in patients with epilepsy (who have an increased content of lipid peroxidation products in the blood).
Simultaneous use of vitamin E in a dose of more than 400 IU/day with anticoagulants (coumarin and indandione derivatives) increases the risk of hypoprothrombinemia and bleeding.
Use of iron preparations in high doses enhances oxidative processes in the body, which increases the need for vitamin E.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Capsules 55 mg+100 mg: 10, 20, 30, 40, or 50 pcs.
Marketing Authorization Holder
Altayvitamins, JSC (Russia)
Dosage Form
| Aevit | Capsules 55 mg+100 mg: 10, 20, 30, 40, or 50 pcs. |
Dosage Form, Packaging, and Composition
| Capsules | 1 caps. |
| Retinyl palmitate (vit. A) | 55 mg (100,000 IU) |
| α-Tocopherol acetate (vit. E) | 100 mg |
10 pcs. – blister packs (1) – cardboard packs.
10 pcs. – blister packs (2) – cardboard packs.
10 pcs. – blister packs (3) – cardboard packs.
10 pcs. – blister packs (4) – cardboard packs.
10 pcs. – blister packs (5) – cardboard packs.
Capsules: 10 and 25 pcs.
Marketing Authorization Holder
Bryntsalov-A, JSC (Russia)
Dosage Form
| Aevit | Capsules: 10 and 25 pcs. |
Dosage Form, Packaging, and Composition
| Capsules | 1 caps. |
| α-Tocopherol acetate | 100 mg |
| 55% oily solution of retinyl palmitate | 0.1 ml |
25 pcs. – dark glass jars (1) – cardboard packs.
25 pcs. – polymer jars (1) – cardboard packs.
10 pcs. – contour blister packs.
25 pcs. – polyethylene bottles.
Capsules 100 mg+58 mg: 20, 30, 40, 500, 840, 1000, 1080, 1260, 1620, 1680, 2000, or 2160 pcs.
Marketing Authorization Holder
Intermed LLC (Russia)
Manufactured By
Biopharmkombinat, LLC (Russia)
Dosage Form
| Aevit | Capsules 100 mg+58 mg: 20, 30, 40, 500, 840, 1000, 1080, 1260, 1620, 1680, 2000, or 2160 pcs. |
Dosage Form, Packaging, and Composition
Capsules soft gelatin, spherical in shape, from yellow to light brown in color, filled with an oily liquid from light yellow to dark yellow in color, without a rancid odor.
| 1 caps. | |
| Tocopherol acetate (vit. E) | 100 mg |
| Retinol (vit. A)* | 58 mg* (100,000 IU) |
* 1 g of Retinol substance (vitamin A palmitate, substance, stabilized with BHA/BHT – oily solution) contains: retinyl palmitate – 1.7 million IU, butylhydroxyanisole (BHA) – 9 mg, butylhydroxytoluene (BHT) – 9 mg.
PRING] sunflower oil – up to 200 mg.
Shell composition (in terms of absolute dry substance) gelatin – 52.75 mg, glycerol – 16.8 mg, methylparahydroxybenzoate – 0.45 mg.
10 pcs. – contour blister packs (2) – cardboard packs.
10 pcs. – contour blister packs (3) – cardboard packs.
10 pcs. – contour blister packs (4) – cardboard packs.
20 pcs. – polyethylene jars (1) – cardboard packs.
30 pcs. – polyethylene jars (1) – cardboard packs.
40 pcs. – polyethylene jars (1) – cardboard packs.
10 pcs. – contour blister packs (50) – cardboard boxes (for hospitals).
10 pcs. – contour blister packs (100) – cardboard boxes (for hospitals).
10 pcs. – contour blister packs (200) – cardboard boxes (for hospitals).
20 pcs. – polyethylene jars (42) – cardboard boxes (for hospitals).
20 pcs. – polyethylene jars (54) – cardboard boxes (for hospitals).
30 pcs. – polyethylene jars (42) – cardboard boxes (for hospitals).
30 pcs. – polyethylene jars (54) – cardboard boxes (for hospitals).
40 pcs. – polyethylene jars (42) – cardboard boxes (for hospitals).
40 pcs. – polyethylene jars (54) – cardboard boxes (for hospitals).
Capsules 100 mg+35 mg: 30 pcs.
Marketing Authorization Holder
Lumi, LLC (Russia)
Dosage Form
| Aevit | Capsules 100 mg+35 mg: 30 pcs. |
Dosage Form, Packaging, and Composition
| Capsules | 1 caps. |
| α-Tocopherol acetate (vit. E) | 100 mg |
| Retinyl palmitate (vit. A) | 35 mg (100000 IU) |
10 pcs. – contour blister packs (3) – cardboard packs.
Capsules: 10, 20, 30, 50, or 100 pcs.
Marketing Authorization Holder
Marbiopharm, JSC (Russia)
Dosage Form
| Aevit | Capsules: 10, 20, 30, 50, or 100 pcs. |
Dosage Form, Packaging, and Composition
Capsules soft gelatin, spherical in shape, from dark yellow to light brown in color, filled with an oily liquid from light yellow to dark yellow in color, without a rancid odor.
| 1 caps. | |
| Retinyl palmitate | 0.055036 g (100000 IU) |
| α-Tocopherol acetate | 0.1 g (100 IU) |
Excipients: sunflower oil – up to 0.2 g.
Capsule shell composition: gelatin – 0.036913 g, glycerol – 0.011865 g, methylparaben – 0.000264 g, instant natural coffee – 0.000958 g.
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (5) – cardboard packs.
10 pcs. – contour cell packs (10) – cardboard packs.
150 pcs. – contour cell packs (1) – cardboard packs.
Capsules 100 mg+55 mg: 10, 20, 30, 40, 100, or 500 pcs.
Marketing Authorization Holder
Meligen FP, CJS (Russia)
Dosage Form
| Aevit | Capsules 100 mg+55 mg: 10, 20, 30, 40, 100, or 500 pcs. |
Dosage Form, Packaging, and Composition
Capsules soft gelatin, spherical in shape, from yellow to light brown in color; the capsule contents are an oily liquid from light yellow to dark yellow in color, without a rancid odor.
| 1 caps. | |
| α-Tocopherol acetate | 100 mg |
| Retinyl palmitate | 35 mg (100 thousand IU) |
Excipients: sunflower oil – 45 mg, gelatin – 44.73 mg, glycerol – 14.67 mg, methylparaben – 0.29 mg, sugar color – 0.31 mg.
10 pcs. – contour cell packs (1) – cardboard packs.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (4) – cardboard packs.
10 pcs. – contour cell packs (10) – cardboard packs.
10 pcs. – contour cell packs (50) – cardboard packs.
Capsules 100 mg+100 thousand IU: 10 or 20 pcs.
Marketing Authorization Holder
Minskintercaps Up (Republic Of Belarus)
Dosage Form
| Aevit | Capsules 100 mg+100 thousand IU: 10 or 20 pcs. |
Dosage Form, Packaging, and Composition
| Capsules | 1 caps. |
| α-Tocopherol acetate | 100 mg |
| Retinyl acetate (or retinyl palmitate) | 100 000 IU |
10 pcs. – blisters (1) – cardboard packs.
10 pcs. – blisters (2) – cardboard packs.
Capsules 100 mg+58 mg: 20, 30, 40, 500, 840, 1000, 1080, 1260, 1620, 1680, 2000, or 2160 pcs.
Marketing Authorization Holder
Tula Pharmaceutical Factory, LLC (Russia)
Dosage Form
| Aevit | Capsules 100 mg+58 mg: 20, 30, 40, 500, 840, 1000, 1080, 1260, 1620, 1680, 2000, or 2160 pcs. |
Dosage Form, Packaging, and Composition
Capsules soft gelatin, spherical in shape, from yellow to light brown in color, filled with an oily liquid from light yellow to dark yellow in color, without a rancid odor.
| 1 caps. | |
| α-Tocopherol acetate | 100 mg |
| Retinyl acetate (vit. A) | 58 mg (100 thousand IU) |
* 1 g of retinyl palmitate (vit. A) substance, stabilized with BHA/BHT contains: retinyl palmitate – 1.7 million IU, butylated hydroxyanisole (BHA) – 9 mg, butylated hydroxytoluene (BHT) – 9 mg.
PRING] sunflower oil – up to 200 mg.
Shell composition (calculated on absolute dry substance) gelatin – 52.75 mg, glycerol – 16.8 mg, methylparaben – 0.45 mg.
10 pcs. – contour cell packs (2) – cardboard packs.
10 pcs. – contour cell packs (3) – cardboard packs.
10 pcs. – contour cell packs (4) – cardboard packs.
20 pcs. – polymer jars (1) – cardboard packs.
30 pcs. – polymer jars (1) – cardboard packs.
40 pcs. – polymer jars (1) – cardboard packs.
10 pcs. – contour cell packs (50) – cardboard boxes (for hospitals).
10 pcs. – contour cell packs (100) – cardboard boxes (for hospitals).
10 pcs. – contour cell packs (200) – cardboard boxes (for hospitals).
20 pcs. – polymer jars (42) – cardboard boxes (for hospitals).
20 pcs. – polymer jars (54) – cardboard boxes (for hospitals).
30 pcs. – polymer jars (42) – cardboard boxes (for hospitals).
30 pcs. – polymer jars (54) – cardboard boxes (for hospitals).
40 pcs. – polymer jars (42) – cardboard boxes (for hospitals).
40 pcs. – polymer jars (54) – cardboard boxes (for hospitals).
Capsules: 10 and 25 pcs.
Marketing Authorization Holder
Pharmalena, CJSC (Russia)
Dosage Form
| Aevit | Capsules: 10 and 25 pcs. |
Dosage Form, Packaging, and Composition
| Capsules | 1 caps. |
| α-Tocopherol acetate | 100 mg |
| 55% oily solution of retinyl palmitate | 0.1 ml |
25 pcs. – dark glass jars (1) – cardboard packs.
25 pcs. – polymer jars (1) – cardboard packs.
10 pcs. – contour cell packs.
25 pcs. – polyethylene bottles.
